@article{89d726d95f764f13a25e1aaa1dd02c13,
title = "Sex and age differences in atrophic rates: An ADNI study with n=1368 MRI scans",
abstract = "We set out to determine factors that influence the rate of brain atrophy in 1-year longitudinal magnetic resonance imaging (MRI) data. With tensor-based morphometry (TBM), we mapped the 3-dimensional profile of progressive atrophy in 144 subjects with probable Alzheimer's disease (AD) (age: 76.5 ± 7.4 years), 338 with amnestic mild cognitive impairment (MCI; 76.0 ± 7.2), and 202 healthy controls (77.0 ± 5.1), scanned twice, 1 year apart. Statistical maps revealed significant age and sex differences in atrophic rates. Brain atrophic rates were about 1%-1.5% faster in women than men. Atrophy was faster in younger than older subjects, most prominently in mild cognitive impairment, with a 1% increase in the rates of atrophy and 2% in ventricular expansion, for every 10-year decrease in age. TBM-derived atrophic rates correlated with reduced beta-amyloid and elevated tau levels (n = 363) at baseline, baseline and progressive deterioration in clinical measures, and increasing numbers of risk alleles for the ApoE4 gene. TBM is a sensitive, high-throughput biomarker for tracking disease progression in large imaging studies; sub-analyses focusing on women or younger subjects gave improved sample size requirements for clinical trials.",
keywords = "Age, Alzheimer's disease, Atrophy rate, Biomarker, Drug trial enrichment, Longitudinal, MRI, Mild cognitive impairment, Neuroimaging, Sex effect, Tensor-based morphometry",
author = "Xue Hua and Hibar, {Derrek P.} and Suh Lee and Toga, {Arthur W.} and Jack, {Clifford R.} and Weiner, {Michael W.} and Thompson, {Paul M.}",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) ( National Institutes of Health Grant U01 AG024904 ). ADNI is funded by the National Institute on Aging , the National Institute of Biomedical Imaging and Bioengineering , and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., and Wyeth, as well as nonprofit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles. Funding Information: This research was also supported by NIH grants P30 AG010129 , K01 AG030514 , and the Dana Foundation . Algorithm development and image analysis for this study was funded by grants to PT from the NIBIB ( R01 EB007813 , R01 EB008281 , R01 EB008432 ), NICHD ( R01 HD050735 ), and NIA ( R01 AG020098 ), and National Institutes of Health through the NIH Roadmap for Medical Research Grants U54-RR021813 (CCB) (to AWT and PT). Author contributions were as follows: XH, DH, SL, AT, and PT performed the image analyses; CJ and MW contributed substantially to the image and data acquisition, study design, quality control, calibration and preprocessing, databasing and image analysis. We thank Anders Dale for his contributions to the image preprocessing and the ADNI project. ",
year = "2010",
month = aug,
doi = "10.1016/j.neurobiolaging.2010.04.033",
language = "English (US)",
volume = "31",
pages = "1463--1480",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "8",
}